Achillion Keeps Focus On Complement Factor D Inhibitors As J&J Exits HCV
J&J's decision to stop HCV development and end its partnership with Achillion has a ripple effect for the smaller biotech's strategy.
You may also be interested in...
The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.
Anthera is exploring strategic alternatives after its lead drug candidate Sollpura failed in Phase III, which means layoffs may be coming soon. Several other biopharma companies have had to turn to job cuts already this year.
Merck adds to its immuno-oncology R&D heft with purchase of Rigontec, while Allergan will collaborate with Lyndra to produce once-weekly drugs for Alzheimer’s disease.